Related Experiment Videos
[Atypical antipsychotics in therapy refractory schizophrenia]
I Schäfer1, M Lambert, D Naber
1Klinik für Psychiatrie und Psychoterapie der Universitätsklinik Hamburg-Eppendorf. schaefer@uke.uni-hamburg.de
Der Nervenarzt
|March 5, 2004
Summary
Treatment resistance in schizophrenia affects many patients. Clozapine remains effective for non-responders, while newer atypical antipsychotics like olanzapine show comparable efficacy and better tolerability in some studies.
Area of Science:
- Psychiatry
- Pharmacology
- Clinical Medicine
Background:
- Treatment resistance is a significant challenge in schizophrenia management, affecting 20-30% of patients partially and 7% completely.
- Clozapine is a well-established treatment for therapy-resistant schizophrenia, despite its restricted use and side effect profile.
Purpose of the Study:
- To review recent double-blind studies comparing newer atypical antipsychotics with clozapine in therapy-resistant schizophrenia.
- To evaluate the efficacy and tolerability of olanzapine, risperidone, and zotepine against clozapine and haloperidol.
Main Methods:
- Analysis of several double-blind studies comparing atypical antipsychotics (risperidone, zotepine, olanzapine) with clozapine.
- Inclusion of studies that directly compared multiple atypical antipsychotics and haloperidol in therapy-resistant populations.
Main Results:
- Clozapine demonstrated increasing superiority with stricter therapy-resistance criteria.
- Olanzapine showed comparable efficacy to clozapine and was better tolerated.
- Study results require careful interpretation due to limited numbers and methodological issues.
Conclusions:
- Clozapine remains a key option for therapy-resistant schizophrenia.
- Olanzapine presents a viable alternative with improved tolerability.
- Further systematic research is needed, especially on combining atypical antipsychotics.